ArticleVeterinary research communications2025
Identification of a mouse-virulent recombinant type I/III Toxoplasma gondii strain in liver cytology of an immunosuppressed cat infected with FeLV-C subgroup.
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and virological effects of the integrase inhibitor raltegravir in cats with naturally progressive feline leukaemia virus infection.Journal of feline medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toxoplasma gondii infection is common in cats, though clinical disease is uncommon and typically occurs in immunocompromised individuals. Till now, there is no specific genotype that can be associated with a certain clinical outcome. A 5-year-old Siamese cat, diagnosed as Feline Leukemia Virus (FeLV)-positive and classified within the FeLV-C subgroup, presented with a two-month history of progressive lethargy, hyporexia, weight loss, and non-regenerative anemia. The cat, a rescued stray with ongoing outdoor access, had previously responded to doxycycline and prednisolone for presumed Mycoplasma spp. infection, but relapsed and began showing signs of discomfort in head and neck regions, consistent with peripheral neuropathy/ encephalitis. Despite treatment with raltegravir, prednisolone, darbopoetin alfa, cyclosporine and clindamycin (although unknown effectiveness of oral administration), clinical deterioration occurred. The cat developed fever, severe anemia, neutropenia, hyperbilirubinemia, hypoglycaemia and elevated ALT activity. Imaging revealed diffuse hepatic changes and a pulmonary interstitial pattern. Liver FNA identified T. gondii organisms, confirmed by qPCR. Despite the initiation of intravenous clindamycin and trimethoprim-sulfamethoxazole, the cat developed seizures, acute respiratory distress, and septic shock, leading to euthanasia. Genotyping of the hepatic T. gondii isolate via targeted NGS at 13 loci revealed a strain with a recombinant type I/III profile. This mosaicism was previously associated with high virulence in mice and also detected in human patients from the same geographical region. This case highlights the variable presentation of toxoplasmosis in cats and contributes to the scarce knowledge of circulating strains in animals. Characterizing the genetic background of strains could identify sources during zoonotic outbreaks and identify genotypes associated with specific clinical manifestations.
Indexed as
Identifiers
41108469What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.